Abbisko Cayman Ltd
Abbisko Cayman Ltd is a biotechnology and medical research company operating in the healthcare sector, primarily engaged in pharmaceuticals and medical research.
Business. Abbisko Cayman Ltd (2256.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. As specific operating segments and geographic details are not provided, the company is described at the industry level. Its primary listing is under the ticker 2256.HK.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Abbisko Cayman Ltd (2256.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. As specific operating segments and geographic details are not provided, the company is described at the industry level. Its primary listing is under the ticker 2256.HK.
### Capital Structure and Liquidity Abbisko Cayman Ltd has a basic and diluted share count of 716.46 million shares, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
### Profitability and Returns No profitability metrics or return ratios are available for Abbisko, which limits the ability to compare its performance against industry benchmarks or cohort medians. This absence of data suggests a lack of transparency or recent financial reporting.
### Segments and Geographic Exposure There is no disclosed segment or geographic revenue breakdown for Abbisko, making it difficult to assess the company's exposure to different markets or product lines. This lack of detail could indicate a single-product or single-market focus, or insufficient disclosure in recent filings.
### Growth Trajectory No specific growth trajectory or revenue history is provided for Abbisko, which limits the ability to project future performance. Analysts have assigned a mean price target of 23.05 CNY and a median of 22.45 CNY, with a mean recommendation of 1.62 (leaning toward buy).
### Risk Factors The primary risk for Abbisko is the inability to assess liquidity due to missing balance-sheet data. Additionally, the lack of profitability and segment data introduces uncertainty about the company's operational health and diversification. Dilution risk is currently low, as the basic and diluted share counts are equal.
### Recent Events No recent filings, transcripts, or notable events are disclosed in the available data, which limits the ability to assess management commentary or strategic shifts.
- Abbisko Cayman Ltd operates in the biotechnology and medical research sector with a high classification confidence.
- The company has no immediate dilution pressure, as basic and diluted share counts are equal.
- Analysts have a generally positive outlook, with a mean recommendation of 1.62 and a mean price target of 23.05 CNY.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- No segment or geographic revenue breakdown is available, limiting visibility into diversification and exposure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥612.1M, +21,4% YoY; Operating income +50,5% YoY.
- ▍Revenue ¥612.1M, +21,4% YoY
- ▍Operating income +50,5% YoY
- ▍Net income +95,4% YoY
- ▍Free cash flow +62,1% YoY
- ▍Net margin 9.0%
Revenue ¥504.0M, +2 544,2% YoY; Operating income +118,5% YoY.
- ▍Revenue ¥504.0M, +2 544,2% YoY
- ▍Operating income +118,5% YoY
- ▍Net income +106,6% YoY
- ▍Free cash flow +110,5% YoY
- ▍Net margin 5.6%
Revenue ¥19.1M; Operating income +12,9% YoY.
- ▍Revenue ¥19.1M
- ▍Operating income +12,9% YoY
- ▍Net income +12,9% YoY
- ▍Free cash flow +15,3% YoY
- ▍Net margin -2264.3%
Revenue ¥0.00, −100,0% YoY; Operating income +72,8% YoY.
- ▍Revenue ¥0.00, −100,0% YoY
- ▍Operating income +72,8% YoY
- ▍Net income +72,6% YoY
- ▍Free cash flow +72,2% YoY
Revenue ¥22.7M; Operating income -¥1.81B.
- ▍Revenue ¥22.7M
- ▍Operating income -¥1.81B
- ▍Net margin -7979.9%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,47 |
| Revenue | —no estimate | —no estimate | 507,9M CNY |
| Operating income | —no estimate | —no estimate | -435,9M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Abbisko Cayman Ltd Market data — financials · 2026-05-26
- Abbisko Cayman Ltd Market data — analyst estimates · 2026-05-26